Recce Pharmaceuticals (ASX:RCE) Trading Down 2.3%

Recce Pharmaceuticals Ltd (ASX:RCE)’s stock price dropped 2.3% during trading on Thursday . The company traded as low as A$0.20 ($0.14) and last traded at A$0.21 ($0.15). Approximately 131,484 shares traded hands during trading, an increase of ∞ from the average daily volume of 0 shares. The stock had previously closed at A$0.22 ($0.15).

The company has a quick ratio of 0.08, a current ratio of 0.09 and a debt-to-equity ratio of 0.41. The firm has a market cap of $23.03 million and a PE ratio of -11.32. The firm’s 50-day moving average price is A$0.21.

About Recce Pharmaceuticals (ASX:RCE)

Recce Pharmaceuticals Ltd, a biotechnology company, researches and develops antibiotic drugs in Australia. The company focuses on the development of RECCE 327 that helps to address the problem of antibiotic resistant superbugs. It also develops drugs for the treatment of stomach ulcers and diarrhea. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017.

Featured Article: Asset Allocation

Receive News & Ratings for Recce Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recce Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.